Trial NCT02117024

View at ClinicalTrials.gov 
Org. Study IDs: HS110-201

Last trial update was posted on 2020-02-05

MeSH Interventions

Cyclophosphamide Docetaxel Erlotinib Hydrochloride Gemcitabine Paclitaxel Pemetrexed Vinorelbine

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

Non Small Cell Lung Cancer

Stopping Reasons

Sponsor Decision; strategic - based on changing treatment landscape

Limitations And Caveats

Study was discontinued prematurely (50% enrollment) by the Sponsor on 01 September 2015 due to changing treatment landscape (PD-1 approvals), and a subsequent change in development focus to IO combinations. See NCT02439450.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID